ARK Investment Management LLC lowered its position in shares of Organovo Holdings, Inc. (NASDAQ:ONVO – Get Rating) by 4.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 291,633 shares of the medical research company’s stock after selling 14,475 shares during the quarter. ARK Investment Management LLC’s holdings in Organovo were worth $703,000 as of its most recent SEC filing.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on shares of Organovo in a report on Sunday. They set a “sell” rating on the stock.
Organovo Price Performance
ONVO stock opened at $2.23 on Tuesday. Organovo Holdings, Inc. has a 52-week low of $1.71 and a 52-week high of $7.41. The company’s 50 day simple moving average is $2.79 and its 200-day simple moving average is $2.82. The firm has a market capitalization of $19.43 million, a P/E ratio of -1.60 and a beta of 1.14.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
- Get a free copy of the StockNews.com research report on Organovo (ONVO)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.